TY - JOUR
T1 - Hairy cell leukaemia
T2 - The role of alpha interferon
AU - Platanias, Leonidas C.
AU - Ratain, Mark J.
N1 - Funding Information:
Acknowledgement - Dr Ratain is a recipient of a Clinical Oncology Career Development Award from the American Cancer Sociery.
PY - 1991/12
Y1 - 1991/12
N2 - Hairy cell leukaemia (HCL) is a chronic progressive disease of predominantly middle-aged men. Alpha interferon has been shown to induce significant responses in HCL patients. With interferon treatment the platelet count normalizes first, followed by the haemoglobin and neutrophil counts. The number of hairy cells in the bone marrow decreases and granulocytic, erythroid and megakaryocytic cells increase. Interferon is well tolerated with the most common side effect being a flu-like syndrome. A number of HCL patients will develop neutralizing antibodies and in these cases the chemotherapeutic agents pentostatin and 2-chlorodeoxyadenosine should be considered. Preliminary results with these agents are promising and further trials are ongoing to confirm their clinical promise.
AB - Hairy cell leukaemia (HCL) is a chronic progressive disease of predominantly middle-aged men. Alpha interferon has been shown to induce significant responses in HCL patients. With interferon treatment the platelet count normalizes first, followed by the haemoglobin and neutrophil counts. The number of hairy cells in the bone marrow decreases and granulocytic, erythroid and megakaryocytic cells increase. Interferon is well tolerated with the most common side effect being a flu-like syndrome. A number of HCL patients will develop neutralizing antibodies and in these cases the chemotherapeutic agents pentostatin and 2-chlorodeoxyadenosine should be considered. Preliminary results with these agents are promising and further trials are ongoing to confirm their clinical promise.
UR - http://www.scopus.com/inward/record.url?scp=0026329151&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026329151&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(91)90575-X
DO - 10.1016/0277-5379(91)90575-X
M3 - Article
C2 - 1799481
AN - SCOPUS:0026329151
SN - 0277-5379
VL - 27
SP - S53-S57
JO - European Journal of Cancer and Clinical Oncology
JF - European Journal of Cancer and Clinical Oncology
IS - SUPPL. 4
ER -